Pinealon Research: EDR, Brain and Sleep Claims
Published
Bookmark this page
Save this article in your browser so you can find it again:
- Computer: Press Ctrl+D (Windows) or ⌘+D (Mac).
- iPhone or iPad: In Safari, tap Share, then Add Bookmark.
- Android: In Chrome, open the menu and tap the star.
Other browsers may use a different menu.
Pinealon research includes cell experiments, animal studies and a small set of human reports. That makes the evidence more complicated than either “proven brain benefits” or “never studied in people.” This guide separates the material studied, the outcomes measured and the questions still unresolved, including claims about memory and sleep.
At a glance:
Pinealon refers to EDR, the three-amino-acid sequence Glu-Asp-Arg.
Epitalon is a different peptide; its literature cannot establish Pinealon's effects.
Human-derived neurons are a laboratory model, not a trial treating people.
The selected literature includes null findings, uncertain human methods and an explicitly preliminary 2026 mouse report.
Publisher disclosure: Bio Research LLC operates Bio Peptides Labs and sells research materials. This commercially interested, AI-assisted summary is not an independent scientific review. Selected sources were checked on November 11, 2026; access limits appear below.

1. What does Pinealon identify?
The original experimental literature identifies Pinealon as the synthetic tripeptide glutamic acid–aspartic acid–arginine, abbreviated Glu-Asp-Arg or EDR. Original cell-study abstract
Epitalon, also called epithalon, instead identifies the four-amino-acid sequence Ala-Glu-Asp-Gly, or AEDG. FDA's July 2026 compounding briefing concerns that separate material. It is neither a Pinealon evaluation nor an approval of Pinealon. Similar names do not make the two peptides interchangeable. FDA Epitalon briefing, identity sections — PDF
When comparing a paper with a material record, check the exact sequence, chemical form and whether the intervention contained other peptides. A name match alone cannot establish the composition of a supplied lot or show that it matches the preparation used in an experiment.
2. What do the original studies show?
The table is a selected evidence map, not an exhaustive literature inventory. Each row answers a different question.
Original report | Model or participants | Finding and important limit |
|---|---|---|
Human occupational groups; peptide interventions described in the abstract | Reported psychoemotional changes, particularly with combined peptides. Baseline group sizes do not establish how many received Pinealon alone. | |
People with multiple conditions; Pinealon and Vesugen studied | Favorable biological-age claims accompanied laboratory findings that complicate a simple antioxidant or safety narrative. | |
Genetically modified mice and brain-tissue measurements | Some dendritic-spine findings favored EDR; electrophysiological trends did not reach statistical significance. Structural measurements are not clinical benefit. | |
Three fibroblast lines from women aged 61, 66 and 68, converted into neurons | EDR affected dendritic morphology and an oxidative-DNA-damage marker. Mitochondrial, lysosomal and p16 measurements did not show improvement. No participants received EDR. | |
Induced neurons derived from fetal mesenchymal stem cells | EDR did not significantly change p21 or the measured senescence-associated beta-galactosidase signal. Results for other peptides cannot be reassigned to EDR. | |
Five mice in the Pinealon group; eight-week intervention | Working-memory performance showed a nonsignificant trend. This preliminary screen does not establish cognitive improvement or lifespan extension. |
The 2021 paper also has a January 2025 correction: two differently described figures originally duplicated the same images. Corrected figures were supplied; the authors stated that their conclusions were unchanged. Readers should use the corrected publication.
3. What can the human reports establish?
The 2012 report initially compared 150 lorry drivers with 150 metal craftsmen. Its abstract later describes peptide-associated changes and favors combined Pinealon and Vesugen. It does not provide enough intervention-level detail to treat all 300 people as a randomized Pinealon trial, or to isolate Pinealon's contribution. 2012 original abstract
The 2015 abstract says 32 people participated, but its listed sex counts total 30. It reports pro-oxidant activity and reduced circulating CD34-positive cells alongside favorable interpretations of biological-age measures. The discrepancy needs clarification, and these laboratory observations do not by themselves establish clinical toxicity or its cause. They also should not disappear from a safety summary. 2015 original abstract
Only the English abstracts of these two Russian-language reports were accessed. Allocation, comparators, individual exposure and adverse-event collection cannot be adequately assessed from those abstracts. Their existence matters; so does the inability to derive a reliable benefit estimate from the accessible information. Our guide to reading peptide studies explains why participant counts and design must be read together.
4. Do brain-cell findings support memory or sleep claims?
A 2014 experiment reported changes in serotonin expression in aging rat brain-cortex cell cultures and proposed a molecular mechanism. It did not measure sleep duration, insomnia symptoms or cognitive performance in people. A neurotransmitter-related laboratory signal cannot answer those clinical questions. Original serotonin-study abstract
Likewise, a neuron extending more processes in a dish is not evidence that a person will recover memory or repair a brain injury. Translation requires evidence about exposure, relevant outcomes and safety in the intended population. Neither a short sequence nor a proposed DNA interaction establishes delivery to the human brain.
The 2026 preprint adds a separate animal screen, not a clinical answer. It disclosed Pump.Science funding and commercial affiliations. Its small, short experiment reported no obvious adverse effects from Pinealon, which cannot establish long-term human safety. Preprint manuscript, results and disclosures
5. What remains unresolved about safety and future research?
The selected evidence does not establish a dependable human side-effect frequency, long-term safety profile or cognitive or sleep benefit. Favorable cell observations and limited laboratory monitoring answer narrower questions. Research materials sold for laboratory work should not be treated as equivalent to clinical preparations or suitable for personal use.
Useful next steps would include clearly characterized materials, exposure studies, independent replication and prospectively registered human studies with appropriate comparators. Those studies should specify clinically meaningful outcomes and systematically collect harms, including follow-up of concerning laboratory signals. These are research priorities, not a treatment recommendation.
For laboratory sourcing, separate the evidence question from the documentation question: what was studied, and what does the supplied lot's testing establish? Our COA, HPLC and mass-spectrometry guide explains the second question. Analytical identity or purity cannot substitute for clinical evidence.
Source-access scope, November 11, 2026: Selected original abstracts, publisher full-text sections, the correction and 2026 preprint full text available through ResearchGate were examined. The human-report full texts were not accessed. Exact-name and sequence searches of ClinicalTrials.gov returned no records for Pinealon, pinealone, “Glu-Asp-Arg” or “EDR peptide.” That bounded registry result does not exclude unregistered or differently indexed research. This was not a systematic review.
